Document is current

Article History

Received: 16 December 2021

Accepted: 5 July 2022

First Online: 12 August 2022

Competing interests

: V.S. reports research funding/grant support for clinical trials from AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, Celgene, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Inhibrx, Loxo Oncology, MedImmune, MultiVir, NanoCarrier, National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, MD Anderson Cancer Center and Vegenics; travel support from ASCO, ESMO, Helsinn Healthcare, Incyte, Novartis and PharmaMar; consultancy/advisory board participation for Helsinn Healthcare, Incyte, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo, and R-Pharm US; and other relationship with Medscape. P.A.C. reports receiving honoraria from Amgen, Blueprint Medicines, Merck Serono, Merck Sharp & Dohme, Novartis, and Roche/Genentech; travel, accommodations and expenses from Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, NETRIS Pharma, Novartis and Roche; non-financial support from Merck Sharpe & Dohme, Novartis and Plexxikon; research funding from Novartis and Merck Sharpe & Dohme; and research funding to institution from AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Innate Pharma, Janssen Pharmaceuticals, Loxo Oncology, Merck Serono, Merck Sharp & Dohme, Novartis, Plexxikon, Roche/Genentech, Taiho Pharmaceutical, Toray Industries and Transgene. S.S. is an advisory board member for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Checkmab, Daiichi-Sankyo, Merck, Roche/Genentech and Seattle Genetics. E.G. reports personal fees from Alkermes, Bristol Myers Squibb, Boehringer Ingelheim, Ellipses Pharma, Genentech, F. Hoffmann-La Roche, Janssen Pharmaceuticals, Merck Sharpe & Dohme, Neomed Therapeutics, Seattle Genetics, TFS Health Science and Thermo Fisher Scientific; research funding from Novartis, Roche and Thermo Fisher Scientific; and travel grants from Glycotope and Menarini. L.P.A. reports personal fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Eli Lilly, Merck, Merck Sharpe & Dohme, Ipsen, Mirati Therapeutics, Novartis, Pfizer, PharmaMar, Roche, Sanofi and Servier; grants from AstraZeneca, Bristol Myers Squibb, Merck Sharpe & Dohme and Pfizer; and other funding from Altum Sequencing and Genomica. P.G. reports a consulting or advisory role for AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Guardant Health, Janssen Pharmaceuticals, Novartis, Merck Sharpe & Dohme, Pfizer, Roche and Takeda; speakers bureau for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, MSD Oncology, Novartis, Pfizer, ROVI, Roche and Takeda; travel, accommodations and expenses support from AstraZeneca, Bristol Myers Squibb and Roche; and research funding from Guardant Health and Sysmex. E.N. reports consulting or advisory role and lectures for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck-Serono, MSD Oncology, Pfizer, Roche and Takeda; and research funding from Bristol Myers Squibb, Merck-Serono, Pfizer and Roche. J.V. reports having consulted and/or having advisory roles for AstraZeneca, Bristol Myers Squibb and Seattle Genetics/Astellas; and institutional research funding from Agendia, Arvinas, Astellas Pharma, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Celldex, Clovis Oncology, Deciphera, Eisai, Exelixis, Fortis, Roche/Genetech, Ignyta, Incyte, Innocrin Pharma, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Polyphor and Rgenix. G.L. reports having consulted and/or having advisory roles for AstraZeneca and Pfizer; received travel, accommodations and expenses from Boehringer Ingelheim, E.R. Squibb & Sons, Janssen Pharmaceuticals and Pfizer; received honoraria from Boehringer Ingelheim; received research funding from AstraZeneca; and received research funding to their institution from AbbVie, Adaptimmune Therapeutics, AstraZeneca, Bavarian Nordic, Blueprint Medicines, Bristol Myers Squibb, Eli Lilly, EMD Serono, G1 Therapeutics, GlaxoSmithKline, Janssen Pharmaceuticals, Merck Sharpe & Dohme, Novartis, Pfizer, Rgenix, Roche/Genentech and Tesaro. G.P.K. received research funding/grant support for clinical trials from AbbVie, Blueprint Medicines, Daiichi, Merck, Cullinan and Takeda. D.W.B. declares no conflicts of interest. M. Seetharam. reports having consulted and/or having an advisory role for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, MorphoSys, Novartis, Roche and Takeda; and received honoraria from Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharpe & Dohme and Novartis; and institutional research funding from AstraZeneca and Bristol Myers Squibb. J.C. declares no conflicts of interest. H.Z. is an employee and shareholder of Blueprint Medicines. J.G. reports having a consulting or advisory role with Arvinas, Blueprint Medicines, Genocea Biosciences and Tesaro. A.Z. is an employee and shareholder of Blueprint Medicines. M. Schuler. reports having a consulting or advisory role for Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Roche, Sanofi and Takeda; having received honoraria from Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis and Roche; having received research funding to his institution from AstraZeneca and Bristol Myers Squibb; and his institution has patents, royalties and other intellectual property of a highly sensitive method for mutation detection by PCR. Y.F. received honoraria as a speaker from AstraZeneca, Bristol Myers Squibb, CStone, Hengrui, Innovent Biologics, Lilly China, Roche, Merck Sharpe & Dohme, Novartis and Pfizer. G.C. reports having a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, Foundation Medicine, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, Samsung, Exact Sciences, Merck and Seagent; having served on speakers bureau for Daiichi-Sankyo, Eli Lilly, Foundation Medicine, Novartis, Pfizer, Roche/Genentech and Samsung; having received travel, accommodations and expenses support from Roche/Genentech, Daichii-Sankyo and Pfizer; having received honoraria from Ellipses Pharma; and having received research funding from Merck.